Physician profile
Bobby G Brown
NPI 1336117183
$594.42
in general payments reported to CMS, 2019-2025
16 companies · $51.28 in 2025
The $51.28 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $141 · 2020: $50.42 · 2021: $214 · 2022: $33.89 · 2023: $74.39 · 2024: $29.04 · 2025: $51.28.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $155.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $154.71 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $216.79 | 2020-2023 | Xarelto |
| Portola Pharmaceuticals, LLC | $122.96 | 2019-2020 | |
| Pfizer INC. | $87.40 | 2019-2021 | |
| Medtronic, INC. | $36.15 | 2025 | Interstim |
| E.R. Squibb & Sons, L.L.C. | $23.76 | 2021 | |
| Bioxcel Therapeutics, INC. | $23.31 | 2023 | Igalmi |
| Penumbra, INC. | $21.60 | 2023 | Indigo System |
| Astrazeneca Pharmaceuticals LP | $16.60 | 2023 | Andexxa |
| Grifols USA, LLC | $15.41 | 2024 | Hyperrab |
| Urogen Pharma, INC. | $15.13 | 2025 | |
| Purdue Pharma L.P. | $13.63 | 2024 | Nalmefene Hydrochloride |
| Medline Industries LP | $1.68 | 2022 |
4 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Bobby Brown listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.